Sarath Raju, MD
Johns Hopkins University School of Medicine
Research Project:
Lung-Specific Cell Free DNA as a Biomarker of Disease Severity and Progression Risk in COPD
Grant Awarded:
- ACRC Pilot Grant
Research Topics:
- biomarkers
- clinical research
- imaging radiology
Research Diseases:
- COPD
- emphysema
Chronic obstructive pulmonary disease (COPD) is a leading cause of death and healthcare expenditure in the United States. Some COPD patients achieve disease stability and have minimal symptoms, while others experience accelerated disease progression. It remains challenging to predict which patients are at higher risk and would benefit from earlier intervention. There is a need to develop non-invasive markers that predict which patients face the greatest risk for adverse outcomes. Cell free DNA (cfDNA) can be measured in the blood and is a promising biomarker of early organ injury. Recently, methods have been developed to identify cfDNA that is specific to the lung and organs of interest, and these tissue and organ-specific biomarkers may ultimately predict adverse outcomes in COPD. We will determine associations between tissue-specific cfDNA and both measures of present severity and future risk for adverse outcomes in COPD. This has the potential to identify high-risk patients and improve clinical care for people with COPD.
Page last updated: October 7, 2024
A Breath of Fresh Air in Your Inbox
Join over 700,000 people who receive the latest news about lung health, including research, lung disease, air quality, quitting tobacco, inspiring stories and more!
Thank You!
You will now receive email updates from the American Lung Association.